Financial Performance - The company's revenue for the first half of 2024 was RMB 408.12 million, a decrease of 21.94% compared to RMB 522.83 million in the same period last year[6]. - Net profit attributable to shareholders for the first half of 2024 was RMB 70.47 million, representing a 2.97% increase from RMB 68.44 million in the previous year[6]. - The net cash flow from operating activities for the first half of 2024 was RMB 27.65 million, a significant recovery from a negative cash flow of RMB 108.75 million in the same period last year[6]. - The total assets as of June 30, 2024, were RMB 2,848.70 million, a decrease of 0.97% from RMB 2,876.69 million at the end of the previous year[6]. - The company's total liabilities as of June 30, 2024, were RMB 2,357.42 million, slightly down from RMB 2,358.56 million at the end of the previous year[5]. - The net assets attributable to shareholders were RMB 2,356.54 million, a minor decrease of 0.04% from RMB 2,357.55 million at the end of the previous year[6]. - The overall operating income of the group has decreased compared to the previous year due to the underperformance of key products[61]. - The group reported a total operating income of ¥408,123,863, a decrease of 21.94% from ¥522,827,706 in the same period last year[64]. - The total comprehensive income attributable to shareholders was RMB 70.48 million, slightly down from RMB 70.61 million in the previous year[146]. Research and Development - The company's R&D expenditure accounted for 38.06% of its operating revenue, an increase of 15.38 percentage points compared to 22.68% in the same period last year[7]. - R&D expenses totaled CNY 155,330,149, an increase of 30.98% compared to the previous year[30]. - The company is focusing on innovative research and development in biomedicine, aiming to become a leader in the industry by addressing clinical treatment gaps[42]. - The company has established advanced technology platforms including gene engineering, photodynamic technology, and nanotechnology, focusing on differentiated competition and maximizing economic benefits[21]. - The company aims to enhance the research and registration of gene engineering technology projects that have entered clinical stages, targeting the commercialization of gene drugs[22]. - The company has filed for 17 new patents during the reporting period, with a total of 213 patents filed to date, of which 96 have been granted[29]. - The company has a strong pipeline in photodynamic therapy, with ongoing research on Ammonium Ketone Acid for treating HPV-related cervical diseases[33]. - The company is exploring new photodynamic compounds to improve efficacy and address existing limitations in treatment[24]. Market and Industry Trends - The Chinese pharmaceutical market is projected to grow from USD 221.4 billion in 2020 to USD 349.8 billion by 2025, reflecting a compound annual growth rate (CAGR) of 11.95%[13]. - The market for broad skin disease treatment and care in China increased from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a CAGR of 11.95%[14]. - The incidence of skin diseases in China is rising, with approximately 150 million patients, highlighting a growing demand for effective treatments[14]. - The global oncology market is expected to reach USD 370 billion by 2027, driven by the introduction of new drugs and biosimilars[16]. - The Chinese market for skin disease treatments is expected to maintain a steady growth trajectory, supported by increasing health awareness and consumer spending[14]. Product Development and Innovation - The company aims to become a leader in the biopharmaceutical industry by focusing on innovative research and development[12]. - The company’s first photodynamic drug, Aira® (aminolevulinic acid), has significantly reduced the recurrence rate of genital warts compared to traditional therapies, filling a clinical gap in treating specific areas[19]. - The global first photodynamic drug for treating hemangiomas, Hemoporfin® (复美达®), was launched in 2017 and has shown high cure rates and low recurrence rates compared to traditional laser treatments[20]. - The company’s photodynamic therapy solutions have been included in major clinical treatment guidelines, indicating their recognition and acceptance in the medical community[19]. - The company has developed a photodynamic therapy platform, with key products including Ela® for treating genital warts and Fumida® for treating port-wine stains, both of which have shown significant market acceptance[23]. - The company is expanding the indications for Ela®, focusing on conditions such as cervical precancerous lesions and acne, and is conducting further research on the molecular mechanisms of photodynamic therapy[24]. - The company is focusing on antibody-drug conjugates, with a total investment of CNY 57,000,000 and significant progress in clinical research[32]. Financial Management and Strategy - The company has adopted a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity[67]. - The company plans to maintain liquidity and enhance overall capital returns through structured deposit investments[83]. - The company is adopting a cautious approach to R&D expenditure capitalization, considering the risks and challenges associated with innovative drug development[60]. - The company plans to pursue international registration for its marketed drugs to support its global expansion strategy[24]. - The company aims to leverage various bidding and centralized procurement opportunities to enhance the marketing capabilities of its products[61]. Corporate Governance and Compliance - The audit committee is responsible for reviewing financial reports and monitoring risk management[103]. - The financial performance for the six months ending June 30, 2024, was reviewed by the audit committee[103]. - The company adheres to applicable accounting standards and Hong Kong Listing Rules[103]. - The corporate governance framework includes various rules and regulations to ensure compliance and transparency[104]. - The company’s financial statements were approved by the board of directors on August 12, 2024, indicating ongoing governance and oversight[158]. Environmental Responsibility - The company invested RMB 797,700 in environmental protection during the reporting period[109]. - The company has established a complete management system for environmental protection, including a leadership team and annual updates to the team member list[112]. - The company has implemented carbon reduction measures, achieving a reduction of 94.92 tons of CO2 equivalent emissions[113]. - The company strictly adheres to national and local standards for pollutant emissions, including wastewater and waste gas, and has implemented comprehensive treatment measures[110]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[110].

Revenue and Profitability - Revenue for the first quarter was RMB 147,647,109, representing a decrease of 21.94% compared to the same period last year[2] - Net profit attributable to shareholders decreased by 73.29% to RMB 2,347,396[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB -4,515,799, a decline of 292.19%[2] - The company's total operating revenue for Q1 2024 was RMB 147,647,109, a decrease of 22% compared to RMB 189,147,552 in Q1 2023[13] - Operating profit for Q1 2024 was RMB 1,190,039, down from RMB 3,481,590 in Q1 2023, reflecting a significant decline in profitability[13] - The net profit attributable to shareholders for Q1 2024 was RMB 2,347,396, compared to RMB 8,787,158 in the same period last year, indicating a decrease of approximately 73%[13] Research and Development - Research and development expenses totaled RMB 64,173,693, an increase of 17.73% year-on-year[2] - R&D expenses accounted for 43.46% of revenue, up by 14.64 percentage points from the previous year[2] - Research and development expenses for Q1 2024 were RMB 63,616,910, an increase from RMB 54,123,028 in Q1 2023, indicating a focus on innovation despite declining revenues[13] Cash Flow and Liquidity - The net cash flow from operating activities was RMB 43,938,388, a significant improvement from RMB -16,026,020 in the same period last year[5] - In Q1 2024, cash inflow from operating activities was RMB 244,729,122, a 50.0% increase from RMB 162,901,241 in Q1 2023[14] - The net cash flow from operating activities was RMB 43,938,388, compared to a negative RMB 160,260,214 in the same period last year[14] - Cash outflow for purchasing goods and services decreased significantly to RMB 82,458,828 from RMB 228,636,546, marking a 64.0% reduction[14] - The net increase in cash and cash equivalents for the quarter was RMB 37,498,452, compared to a decrease of RMB 401,292,835 in Q1 2023[14] - The ending balance of cash and cash equivalents was RMB 1,233,394,449, up from RMB 888,009,829 in the previous year[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,825,346,356, a decrease of 1.78% from the end of the previous year[2] - Total current assets decreased to RMB 1,833,318,779 from RMB 1,869,424,886, reflecting a decline of about 2%[11] - Total liabilities decreased to RMB 464,492,233 as of March 31, 2024, down from RMB 518,124,139 at the end of 2023, representing a reduction of approximately 10%[12] - Equity attributable to shareholders increased slightly by 0.10% to RMB 2,359,932,124[2] Strategic Changes - The company terminated its cooperation with a promotional service provider, impacting sales revenue of a key product during the reporting period[5] - The company plans to terminate its marketing cooperation with Shanghai Huizheng due to underperformance of its product, Liboduo, which has led to a significant drop in revenue[10] - The company is adjusting its sales strategy for Liboduo by selecting specialized CSO companies for regional marketing and academic promotion to enhance communication efficiency and reduce operational risks[10] - The company aims to leverage various bidding and procurement opportunities to enhance its market presence and adapt its promotional strategies to local conditions[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,860[8] Cash Flow from Investments - Cash inflow from investment activities was RMB 919,724,441, down 13.0% from RMB 1,055,510,659 in Q1 2023[14] - The net cash flow from investment activities was negative RMB 3,807,572, an improvement from negative RMB 235,735,353 year-over-year[14] Financing Activities - Cash outflow related to financing activities decreased to RMB 2,669,076 from RMB 5,251,044, a reduction of 49.2%[14] Accounting Standards - The company has not applied new accounting standards or interpretations for the first quarter of 2024[15]

复旦我江 FUDAN-ZHANGJIANG 上 海 復 旦 張 江 生 物 醫 藥 股 份 有 限 公 司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) (股票號碼：1349) 2023 報 * 僅供識別 目錄 | --- | --- | --- | --- | |-------|-------|----------------------------|--------| | | | | | | | | | | | | | 公司資料 | 頁碼 2 | | | | 五年財務摘要 | 4 | | | | 主席報告 | 6 | | | | 管理層的討論及分析 | 19 | | | | 董事會報告 | 36 | | | | 監事會報告 | 66 | | | | 審核委員會報告 | 68 | | | | 薪酬委員會報告 | 71 | | | | 提名委員會報告 | 73 | | | | 戰略委員會報告 | 75 | | | | 企業管治報告 | 77 | | | | 董事、監事及高級管理層簡介 | 108 | | ...

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 850,733,000, a decrease of 17.5% compared to RMB 1,031,160,000 in 2022[2] - Profit before tax for the same period was RMB 97,528,000, down 26.3% from RMB 132,294,000 in the previous year[2] - The net profit attributable to shareholders for 2023 was RMB 108,627,000, a decline of 21.3% from RMB 137,997,000 in 2022[2] - The company reported a total comprehensive income of RMB 107,793,000 for 2023, compared to RMB 136,122,000 in 2022, indicating a decline of 20.8%[2] - The total operating profit for 2023 was RMB 45,580,116, down from RMB 105,919,554 in 2022[13] - The company reported a net financial loss of ¥3,703,638 in 2023, compared to a loss of ¥8,788,607 in 2022, showing an improvement[188] - The total profit for 2023 was RMB 97,528,063, a decrease of 26.3% compared to RMB 132,293,548 in 2022[197] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 2,876,688,000, a decrease from RMB 2,976,007,000 in 2022[3] - Total liabilities decreased to RMB 518,124,000 in 2023 from RMB 722,986,000 in 2022, representing a reduction of 28.3%[3] - Cash and cash equivalents as of December 31, 2023, were RMB 1,195,895,997, down from RMB 1,289,302,664 in 2022[4] - The company's total equity attributable to shareholders increased to RMB 2,357,554,000 in 2023 from RMB 2,257,102,000 in 2022, marking an increase of 4.4%[3] - The company's total equity as of December 31, 2023, was RMB 2,358,563,368, an increase from RMB 2,253,021,355 at the end of 2022[18] - The company's total equity as of December 31, 2023, was RMB 2,379,229,295, an increase from RMB 2,321,921,130 at the end of 2022[20] Earnings Per Share - The company's basic and diluted earnings per share for 2023 were RMB 0.1051, down from RMB 0.1340 in 2022, reflecting a decrease of 21.5%[2] - Basic earnings per share for 2023 were RMB 0.11, down from RMB 0.13 in 2022, a decrease of 15.4%[12] - Diluted earnings per share remained at RMB 0.11 for 2023, unchanged from 2022 despite adjustments for potential ordinary shares[200] Cash Flow - Cash flow from operating activities for 2023 was RMB 71,015,450, down from RMB 165,268,622 in 2022[14] - The net cash flow from operating activities in 2023 was RMB 10,422,159, down from RMB 122,058,916 in 2022, indicating a significant decline[15] - The total cash inflow from investment activities in 2023 was RMB 3,835,875,490, an increase of 10.5% from RMB 3,469,785,915 in 2022[15] - The cash outflow for investment activities in 2023 was RMB 3,848,247,323, compared to RMB 3,500,564,593 in 2022, reflecting a rise of 9.9%[15] - The company's cash balance at the end of 2023 was RMB 1,067,294,432, down from RMB 1,187,769,137 at the end of 2022[15] Research and Development - Research and development expenses increased to RMB 243,762,975 in 2023, compared to RMB 226,850,903 in 2022, reflecting a growth of 7.4%[10] - The total research and development expenses for 2023 were RMB 244,700,356, an increase from RMB 233,659,131 in 2022[145][146] - R&D expenses for 2023 totaled ¥94,014,517, slightly down from ¥95,009,511 in 2022, while salary expenses in R&D increased to ¥75,383,005 from ¥57,590,255[187] Inventory and Receivables - The inventory increased to RMB 29,993,697 in 2023 from RMB 19,268,923 in 2022, an increase of 55.5%[9] - The provision for bad debts increased to RMB 35,993,681 as of December 31, 2023, compared to RMB 12,365,732 on December 31, 2022, reflecting a significant rise in credit loss provisions[98][102] - The aging analysis of accounts receivable shows that the amount overdue within one year was RMB 476,025,167, down from RMB 516,855,117 in the previous year, indicating improved collection efficiency[99] - The total amount of accounts receivable written off during the year was RMB 271,600, with a corresponding bad debt provision of the same amount[106] Government Grants and Taxation - The company received government subsidies related to income amounting to ¥20,638,461 in 2023, compared to ¥7,868,017 in 2022, indicating a substantial increase[191] - The corporate income tax rate applicable to the company for 2023 remains at 15%, consistent with 2022[90] - The company has received the "High-tech Enterprise Certificate" valid for three years, allowing it to maintain the reduced corporate income tax rate of 15%[89] Accounting Policies and Compliance - The company has updated its accounting policies in accordance with the Ministry of Finance's guidelines, which did not have a significant impact on the financial statements[3] - The financial statements were approved by the board of directors on March 28, 2024, indicating a commitment to transparency and compliance[23] - The company’s accounting policies are aligned with the Chinese Accounting Standards and reflect its operational characteristics[24] Shareholder Information - The company distributed dividends totaling RMB 72,560,047 to shareholders in 2023[18] - The company declared a cash dividend of RMB 0.07 per share for the 2022 fiscal year, totaling RMB 72,560,047 based on 1,036,572,100 shares issued[179]

Financial Performance - Operating revenue for Q3 2023 was RMB 185,132,977, a decrease of 58.40% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2023 was RMB 21,454,125, down 70.53% year-on-year[2] - Basic earnings per share for Q3 2023 was RMB 0.02, down 71.43% year-on-year[2] - Total operating revenue for the first three quarters of 2023 was RMB 707,960,683, a decrease of 1.4% compared to RMB 716,265,980 in the same period of 2022[10] - Net profit for the first three quarters of 2023 increased significantly to RMB 89,811,290, compared to RMB 36,739,951 in the same period of 2022, representing a growth of 144.5%[10] - Basic and diluted earnings per share rose to RMB 0.09, up from RMB 0.04 in the previous year[10] Research and Development - R&D investment totaled RMB 50,730,733 in Q3 2023, a decrease of 28.58% compared to the same period last year, representing 27.40% of operating revenue[2] - The proportion of R&D investment to operating revenue increased by 11.44 percentage points in Q3 2023 compared to the same period last year[2] Cash Flow and Liquidity - Net cash flow from operating activities for the year-to-date period was RMB 1,712,208, a significant decline of 99.13% compared to the previous year[2] - Cash flow from operating activities generated a net amount of RMB 1,712,208, a decrease from RMB 196,182,795 in the same period last year[12] - Cash flow from investing activities resulted in a net outflow of RMB 35,490,426, an improvement from a net outflow of RMB 79,977,072 in the previous year[12] - Cash and cash equivalents stood at RMB 1,242,462,297, down from RMB 1,289,302,664, a decrease of 3.6%[8] - Cash and cash equivalents at the end of the period totaled RMB 1,242,462,297, slightly up from RMB 1,237,143,906 at the end of the same period last year[12] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,946,016,262, a decrease of 1.01% from the end of the previous year[2] - Total current assets amounted to RMB 1,950,086,202, a decrease of 5.7% from RMB 2,069,188,785 on December 31, 2022[8] - Total non-current assets increased to RMB 995,930,060 from RMB 906,818,487, reflecting a growth of 9.8% year-over-year[8] - Total liabilities decreased to RMB 609,240,398 from RMB 722,985,917, representing a reduction of 15.8%[9] - Shareholders' equity increased to RMB 2,336,775,864 from RMB 2,253,021,355, marking an increase of 3.7%[9] Operational Insights - The company experienced significant sales fluctuations in Q2 and Q3 2023 due to external environmental impacts, although cumulative sales remained stable[4] - The company reported a significant reduction in management expenses to RMB 39,075,379, down from RMB 55,061,168 year-over-year, reflecting a cost control strategy[10] - The company has not reported any new product developments or market expansions during this period[10] Inventory and Receivables - Accounts receivable rose to RMB 524,153,117 from RMB 506,383,690, an increase of 3.0%[8] - Inventory increased to RMB 41,127,892 from RMB 40,526,760, reflecting a growth of 1.5%[8]

Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[6]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[6]. - Basic earnings per share for the first half of 2023 were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[7]. - The company achieved a revenue of CNY 523 million during the reporting period, representing a year-on-year growth of 92.74%[43]. - The total comprehensive income for the period was RMB 68.50 million, a significant improvement from a loss of RMB 36.73 million in the previous year[140]. - The company reported a gross profit of RMB 481.25 million, with a gross margin of approximately 92%[139]. - The company reported a total cash inflow from operating activities of RMB 416,844,233, up from RMB 397,751,452 in the previous year[145]. Cash Flow and Liquidity - The company's net cash flow from operating activities was negative RMB 108.75 million, a decline from a positive RMB 59.37 million in the same period last year, indicating a 283.19% decrease[6]. - Cash and cash equivalents stood at RMB 1,231,128,499 as of June 30, 2023, indicating strong liquidity[60]. - The cash balance at the end of June 30, 2023, was RMB 1,148,276,143, compared to RMB 1,084,972,748 at the end of June 30, 2022[147]. - The company experienced a net cash decrease of RMB 39,492,994 during the period, contrasting with an increase of RMB 1,713,377 in the same period last year[147]. Research and Development - The research and development expenditure accounted for 22.68% of the operating revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[7]. - Research and development expenses for the current period amounted to approximately CNY 118.59 million, representing a 10.99% increase compared to the previous year[32]. - The company has established advanced research and development platforms, including gene engineering, photodynamic technology, and nanotechnology, focusing strategically on photodynamic drugs and antibody-drug conjugates[20]. - The company has developed multiple products based on its gene engineering technology platform, including cytokines, fusion proteins, monoclonal antibodies, and antibody-drug conjugates (ADCs) to address unmet clinical needs[21]. Market and Industry Trends - The prevalence of skin diseases in China has been increasing, with approximately 150 million patients reported[12]. - The market size for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate (CAGR) of 11.95%[12]. - The global pharmaceutical market is projected to grow at a CAGR of 3-6% from 2023 to 2027, potentially reaching approximately USD 1.9 trillion[12]. - The incidence of malignant tumors in China is significant, with lung cancer being the most prevalent, accounting for a large portion of new cases[15]. Product Development and Innovation - The company aims to be an innovator and leader in the biopharmaceutical industry, focusing on exploring clinical treatment gaps and providing effective therapeutic solutions[11]. - The company’s photodynamic therapy products have filled a significant treatment gap for specific areas, such as the urethra and anal canal, where effective therapies were previously lacking[17]. - The company is focusing on the clinical application of ALA-fluorescence-guided techniques for surgical procedures, particularly for brain gliomas and bladder cancer[24]. - The company aims to leverage the unique advantages of photodynamic drugs to develop new therapeutic solutions for currently untreatable diseases[23]. Corporate Governance and Management - The company has complied with all applicable provisions of the corporate governance code, except for the separation of the roles of chairman and CEO[92]. - The company aims to enhance its governance structure and establish a long-term incentive mechanism to attract and retain management and core technical personnel[79]. - The company has appointed new executives, including a new executive director and vice president, as of May 30, 2023[82]. - The audit committee reviewed the financial performance and ensured compliance with applicable accounting standards and Hong Kong listing rules[90]. Environmental Responsibility - The company invested ¥1.0397 million in environmental protection during the reporting period[96]. - The company has established a comprehensive environmental management system, including regular monitoring of wastewater and air emissions[96]. - The company has implemented strict waste management protocols, including registration with local solid waste management systems[97]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[96]. Shareholder Information - The company has a total of 38 million restricted stock options under the incentive plan, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[79]. - The company reported a total of 38 million shares granted under the equity incentive plan, with 14.7 million shares becoming invalid due to unmet performance targets or employee departures[82]. - The company completed the registration of the first vesting period shares of the restricted stock incentive plan on May 12, 2023, issuing 7,572,100 A-shares[79]. - The top ten shareholders hold a total of 1,000,000,000 shares, representing approximately 97.16% of the total shares[119].

Financial Performance - The company reported a revenue of RMB 522.83 million for the first half of 2023, representing a 92.74% increase compared to RMB 271.26 million in the same period last year[5]. - Net profit attributable to shareholders was RMB 68.44 million, a significant recovery from a loss of RMB 35.97 million in the previous year[5]. - Basic earnings per share for the period were RMB 0.07, compared to a loss of RMB 0.03 per share in the same period last year[6]. - The company achieved a pre-tax profit of RMB 63.43 million, recovering from a loss of RMB 61.19 million in the same period last year[3]. - The company’s comprehensive income attributable to shareholders was RMB 68.33 million, compared to a loss of RMB 36.68 million in the same period last year[3]. - Operating revenue increased to RMB 522,827,706, a 92.74% increase compared to RMB 271,259,675 in the same period last year[51]. - The total profit for the period was RMB 63,432,798, a significant recovery from a loss of RMB 61,189,485 in the same period last year[127]. - The company reported a net loss of RMB 36,020,882 for the six months ended June 30, 2022, which highlights the financial challenges faced in that period[136]. Assets and Liabilities - The company's total assets reached RMB 3.03 billion, up 1.85% from RMB 2.98 billion at the end of the previous year[4]. - Total liabilities stood at RMB 716.04 million, slightly down from RMB 722.99 million in the previous year[4]. - Cash and cash equivalents as of June 30, 2023, totaled RMB 1,231,128,499, significantly exceeding the outstanding loan balance[54]. - The company has no asset pledges as of June 30, 2023[57]. - The total assets of Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. are RMB 565,336,994, with a net profit of RMB 14,787,447[64]. - The company's total liabilities decreased slightly to RMB 716,037,743 from RMB 722,985,917, indicating a reduction of about 0.13%[122]. - The company’s total equity increased to RMB 2,314,975,432 from RMB 2,253,021,355, reflecting a growth of approximately 2.75%[122]. Research and Development - Research and development expenses accounted for 22.68% of revenue, a decrease of 16.71 percentage points from 39.39% in the previous year[6]. - The company has invested a total of approximately ¥118.59 million in R&D, representing a 10.99% increase compared to the previous period[30]. - The company is focusing its R&D on innovative drugs for skin diseases, tumors, and autoimmune diseases, with a strategic emphasis on photodynamic drugs and antibody-drug conjugates[48]. - The company has established a gene engineering technology platform, focusing on the development of monoclonal antibodies and antibody-drug conjugates (ADC), which are key areas for future commercialization[20]. - The company’s research and development strategy emphasizes addressing unmet clinical needs and achieving differentiated competition through innovative drug development[19]. - The company is conducting Phase I clinical trials for multiple antibody-drug conjugates (ADCs) targeting various cancers, including DM1 for CD30, SN38 for Trop2, and BB05 for Her2, with the first patient enrolled in January 2023 for the BB05 project[21]. - The company has established a nanotechnology platform, with the liposomal formulation里葆多® launched in 2009, and has received acceptance for consistency evaluation of its doxorubicin liposome injection[25]. Market and Industry Trends - The global pharmaceutical market is expected to grow at a compound annual growth rate (CAGR) of 3-6% from 2023 to 2027, reaching approximately $1.9 trillion[10]. - The Chinese pharmaceutical market's CAGR from 2016 to 2020 was 3.70%, with a total market size of $221.4 billion in 2020, projected to reach $349.8 billion by 2025 and $457.4 billion by 2030[10]. - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion to RMB 471.8 billion from 2017 to 2021, with a CAGR of 11.95%[11]. - The incidence of malignant tumors remains a significant health threat, with lung cancer being the most prevalent, accounting for a substantial portion of new cases in China[14]. - The global oncology spending is projected to reach $370 billion by 2027, driven by the introduction of new drugs and biosimilars[14]. Risks and Challenges - The company faces risks related to new drug development, which can take over ten years and involve significant costs and uncertainties[43]. - The company has a risk of core technical personnel turnover, which could impact its competitive advantage and stability in R&D and production services[44]. - The company may face drug price reduction risks due to government policies and market competition, which could negatively impact revenue[47]. - The company is exposed to potential foreign exchange risks, although most transactions occur in the domestic market[46]. Corporate Governance and Shareholder Matters - The company has established a three-year dividend return plan for shareholders from 2023 to 2025[71]. - The company has completed the nomination of candidates for the eighth board of directors and the supervisory board, with elections held on May 30, 2023[72]. - The company has recognized new core technical personnel, including Li Xiaowen, Yu Daiqing, Chen Yu, and Yang Tong, based on their contributions to R&D and business development[73]. - The company has a restricted stock incentive plan that includes a total of 38 million shares, with 32.77 million shares granted in the first grant and 5.23 million shares reserved for future grants[75]. - The company has not reported any changes in controlling shareholders or actual controllers during the reporting period[119]. Environmental and Social Responsibility - The company has established a comprehensive environmental management system and adheres to national and local standards for pollutant emissions, with no violations reported during the reporting period[88][90]. - The company has implemented strict measures for wastewater treatment, ensuring compliance with the Biopharmaceutical Industry Pollutant Discharge Standards[89]. - The company is committed to sustainable development and has set five-year environmental goals based on 2020 levels to enhance its environmental management[90]. - The company has implemented carbon reduction measures, achieving a reduction of 117.651 tons of CO2 equivalent emissions[91]. Financial Management - The total amount raised from the IPO was RMB 1,074 million, with a net amount of RMB 974.32 million after deducting issuance costs[98]. - The company approved the use of RMB 96 million of excess raised funds for replenishing working capital[100]. - The company plans to manage temporarily idle raised funds, with a maximum of RMB 350 million allocated for cash management in safe and liquid investment products[101]. - The company’s financial strategies are focused on enhancing profitability and safeguarding shareholder interests[102].

Financial Performance - Revenue for the first quarter reached RMB 189,147,552, representing a year-on-year increase of 34.33%[2] - Net profit attributable to shareholders was RMB 8,787,158, an increase of 78.39% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 2,349,656, reflecting a significant increase of 252.85%[2] - Operating profit for Q1 2023 was 3,481,590, a significant recovery from a loss of 1,492,333 in Q1 2022[11] - Net profit for Q1 2023 was 8,794,123, compared to 4,810,020 in Q1 2022, reflecting a year-over-year increase of 83.5%[11] - The company reported a basic and diluted earnings per share of 0.01 for Q1 2023, compared to 0.00 in Q1 2022[11] Research and Development - Research and development expenses totaled RMB 54,511,436, accounting for 28.82% of revenue, a decrease of 6.49 percentage points from the previous year[2] - Research and development expenses increased to 54,123,028, up from 48,439,435, indicating a focus on innovation[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,850,342,292, a decrease of 4.22% from the end of the previous year[2] - Total current assets decreased to 1,863,871,518 from 2,069,188,785, a decline of 9.9%[9] - Total liabilities decreased from 722,985,917 to 588,372,864, a reduction of 18.6%[10] - Cash and cash equivalents decreased from 1,289,302,664 to 888,009,829, a decline of 31.1%[9] - Total assets decreased from 2,976,007,272 to 2,850,342,292, a decline of 4.2%[10] Cash Flow - The net cash flow from operating activities was negative at RMB -160,260,214, primarily due to payments made to suppliers from the previous year[4] - In Q1 2023, cash inflow from operating activities was 162,901,241, down 18.9% from 200,904,381 in Q1 2022[13] - Cash outflow for purchasing goods and services increased significantly to 228,636,546, compared to 112,337,883 in the same period last year, representing a 103.6% increase[13] - Net cash flow from operating activities was -160,260,214, worsening from -17,207,380 in Q1 2022[13] - Cash inflow from investment activities totaled 1,055,510,659, slightly up from 1,054,566,056 in Q1 2022[13] - Cash outflow for investment activities rose to 1,291,246,012, compared to 1,094,314,314 in the previous year, marking an 18% increase[13] - Net cash flow from investment activities was -235,735,353, compared to -39,748,258 in Q1 2022[13] - Cash flow from financing activities resulted in an outflow of 5,251,044, up from 2,161,665 in Q1 2022[13] - The net increase in cash and cash equivalents was -401,292,835, compared to -59,130,975 in the same quarter last year[13] - The ending balance of cash and cash equivalents was 888,009,829, down from 1,149,749,936 in Q1 2022[13] Shareholder Information - The company reported a total of 21,986 shareholders at the end of the reporting period[6] Government Subsidies - The company received government subsidies amounting to RMB 3,216,857, which are closely related to its normal business operations[3] Product and Market Development - Major products sales improved during the reporting period, contributing to the overall revenue growth[4] - The company has not reported any new products or technologies, market expansions, or mergers in this quarter[14]

Financial Performance - Total revenue for 2022 was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[7] - Profit before tax for 2022 was RMB 132,294,000, down 38.8% from RMB 215,921,000 in 2021[7] - Net profit attributable to shareholders for 2022 was RMB 137,997,000, a decrease of 35.4% compared to RMB 213,296,000 in 2021[7] - The basic and diluted earnings per share attributable to shareholders for 2022 was RMB 0.1340, down from RMB 0.2049 in 2021[7] - The company's net profit for 2022 was approximately RMB 137,272 thousand, a decline of about 35% from RMB 212,381 thousand in 2021, resulting in a net profit margin of 13% compared to 19% in the previous year[79] - The cost of goods sold for 2022 was RMB 84,062 thousand, up from RMB 80,899 thousand in 2021, with the cost-to-revenue ratio increasing from 7% to 8%[68] - Sales expenses for 2022 were RMB 554,631 thousand, an 8% decrease from RMB 599,697 thousand in 2021, while the ratio of sales expenses to revenue increased from 53% to 54%[69] - Research and development expenses for 2022 amounted to RMB 226,851 thousand, a 1% increase from RMB 224,387 thousand in 2021, while total R&D investment decreased by 6% to RMB 233,659 thousand[70] - Other income for 2022 was RMB 10,465 thousand, a decrease of 52% from RMB 21,687 thousand in 2021, attributed to a reduction in government subsidies[75] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 2,976,007,000, an increase of 7% from RMB 2,781,172,000 in 2021[9] - Total liabilities as of December 31, 2022, were RMB 722,986,000, an increase of 22.2% from RMB 591,582,000 in 2021[9] - As of December 31, 2022, the company's long-term equity investments had a net book value of RMB 305,767 thousand, with an investment loss of approximately RMB 19,800 thousand recorded during the reporting period[81] - As of December 31, 2022, the company had cash and cash equivalents of approximately RMB 1,289,303 thousand, an increase from RMB 1,208,881 thousand at the end of 2021[94] Research and Development - The company aims to become an innovator and leader in the biopharmaceutical industry, focusing on effective treatment solutions[12] - The company emphasizes the importance of new drug development as a reflection of value creation in the pharmaceutical industry[12] - The company plans to continue exploring clinical treatment gaps and providing more effective therapeutic options[12] - The company has a strong commitment to addressing unmet clinical needs through innovative drug development[16] - The company has established a gene engineering technology platform, focusing on developing cytokine, fusion protein, monoclonal antibody, and antibody-drug conjugate products to meet unmet clinical needs[174] - The company has established a nanotechnology platform for drug development, focusing on liposomal formulations to enhance drug solubility and bioavailability, addressing significant technical barriers in the industry[177] - The company has maintained a balance between innovative and generic drug development, ensuring that its projects meet clinical needs and demonstrate unique therapeutic effects[171] Clinical Trials and Product Development - The company is a leader in the development of photodynamic drugs, with ongoing research targeting skin diseases, tumors, and precancerous lesions[16] - The product ALA® has been successfully commercialized and is now the preferred clinical drug for treating condyloma acuminatum, with multiple new indications being explored[17] - Clinical research for ALA® in treating cervical precancerous lesions has shown significant progress, with a new optimized Phase II clinical study plan developed[20] - The company is conducting Phase II clinical trials for ALA® in treating moderate to severe acne, focusing on pain-free treatment options[20] - The company has initiated Phase II clinical trials for ALA® in treating glioblastoma, confirming its potential clinical benefits[20] - The product Revamed® (Heimofen) is the world's first photodynamic drug for treating capillary malformations, with ongoing Phase II clinical trials in the U.S.[22] - The company's first ADC drug, targeting CD30, completed Phase I clinical trials and is now undergoing an expansion Phase I trial for relapsed/refractory CD30-positive peripheral T-cell lymphoma[26] - The ADC drug targeting Trop2 for triple-negative breast cancer, bladder cancer, and gastric cancer is currently in Phase I clinical research, aiming to achieve similar clinical results as the original drug[28] - The ADC drug targeting HER2 for metastatic breast cancer and gastric cancer has initiated Phase I clinical research, with the first subject enrolled in January 2023[29] - The company has developed a new linker-drug platform (BB05 platform) to support the development of Me-better or innovative ADC drugs[28] - The Parkinson's disease controlled-release drug project (WD-1603) completed Phase II clinical research and is expected to enter Phase III trials soon, utilizing the UGi-Pump® technology[30] - The small molecule JAK1 selective inhibitor for rheumatoid arthritis is currently in Phase I clinical research, with additional projects for atopic dermatitis and ulcerative colitis in Phase II[31] - The company has received approval for a topical JAK1 selective inhibitor for atopic dermatitis to commence Phase I clinical trials[31] Market and Industry Trends - The global pharmaceutical market is projected to exceed USD 1.1 trillion by 2024, with a compound annual growth rate of 3-6% expected until 2026[59] - By 2025, the Chinese pharmaceutical market is estimated to reach RMB 2.1 trillion, with the biopharmaceutical market expected to account for 48%[59] - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a CAGR of 11.95%[153] - The global oncology drug expenditure is projected to reach $370 billion by 2027, driven by the acceleration of new drug launches and biosimilars[157] - In China, approximately 2.2 million new cancer cases are reported annually, with a mortality rate of 1.6 million, indicating a 20% annual increase in incidence and mortality over the past two decades[157] Corporate Governance and Strategy - The company emphasizes the importance of balancing innovative drug development with shareholder interests[14] - The company has implemented a restricted stock incentive plan in 2021, incurring share-based payment expenses of approximately RMB 7,689 thousand during the reporting period[79] - The company believes that the structured deposit agreements with banks will yield more favorable returns compared to traditional deposits[114] - The board of directors has approved the incentive plan to enhance the motivation and creativity of the employees involved[118] - The company has a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity and financial arrangements[94] - The company has no significant contingent liabilities or asset pledges as of December 31, 2022[86][87] Challenges and Risks - The company faced challenges in production and sales due to unexpected factors, impacting the normal operation of research and development projects[65] - The company faces risks related to new drug development, with a lengthy process that can take over ten years and significant uncertainty regarding the success of products in clinical trials[185] - The company’s product range is relatively narrow, with three main products contributing significantly to total revenue, which poses a risk if these products face competitive pressures or regulatory challenges[187] - Recent policies have led to a decline in drug prices, increasing competition and potential revenue impacts for the company, although its products are not currently subject to these price reductions[188] Dividend Policy - The company plans to distribute a final dividend of RMB 0.07 per share for the year ended December 31, 2022, totaling approximately RMB 72.03 million (including tax) based on 1,029,000,000 shares issued[197] - The proposed dividend distribution will be subject to approval at the annual general meeting scheduled for May 30, 2023[197] - The company has implemented a stable and proactive profit distribution policy since 2015, aiming for a cash dividend ratio of no less than 10% of the distributable profit in the first three years post-IPO[194] - The board of directors will consider the impact of cash dividends on the company's operational funding needs and any significant cash expenditures in the next twelve months[196]

Financial Performance - The company's revenue for the year ended December 31, 2022, was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[2] - Profit before tax for 2022 was RMB 132,294,000, down 38.7% from RMB 215,921,000 in the previous year[2] - The total comprehensive income attributable to shareholders for 2022 was RMB 136,847,000, a decline of 34.8% from RMB 210,016,000 in 2021[2] - The company's basic and diluted earnings per share for 2022 were RMB 0.1340, down from RMB 0.2049 in 2021, reflecting a decrease of 34.3%[2] - Net profit for 2022 was RMB 137,272,198, down from RMB 212,380,705 in 2021, representing a decline of 35.3%[13] - Total revenue for 2022 was $929.03 million, a decrease of 8.96% from $1,020.67 million in 2021[18] - Net profit for 2022 was $102.04 million, down 41.06% from $173.22 million in 2021[18] - Operating profit decreased to $105.92 million in 2022, compared to $177.03 million in 2021, reflecting a decline of 40.06%[18] Assets and Liabilities - The company's total assets as of December 31, 2022, amounted to RMB 2,976,007,000, an increase from RMB 2,781,172,000 in 2021[4] - Total liabilities increased to RMB 722,986,000 in 2022 from RMB 591,582,000 in 2021, representing a rise of 22.2%[4] - The company's total liabilities reached RMB 678,689,845 in 2022, an increase of 25.9% from RMB 539,099,929 in 2021[11] - Current liabilities rose to RMB 633,102,882 in 2022, compared to RMB 482,246,500 in 2021, an increase of 31.3%[11] - The company's total equity attributable to shareholders was RMB 2,257,102,000 as of December 31, 2022, compared to RMB 2,192,946,000 in 2021, showing an increase of 2.9%[8] Cash and Cash Equivalents - Cash and cash equivalents as of December 31, 2022, were RMB 1,289,302,664, up from RMB 1,208,880,911 in 2021[6] - Cash flow from operating activities for 2022 was $165.27 million, a decrease of 38.43% from $268.90 million in 2021[21] - The company reported cash and cash equivalents at year-end 2022 of $1.29 billion, an increase from $1.21 billion at the end of 2021[23] - Cash and bank deposits as of December 31, 2022, amount to RMB 1,289,258,185, an increase from RMB 1,208,855,545 in 2021[126] Research and Development - Research and development expenses increased slightly to RMB 226,850,903 in 2022 from RMB 224,387,287 in 2021, indicating a focus on innovation[13] - Research and development expenditures are classified into research phase and development phase, with development costs capitalized only if specific criteria are met[87] - Research and development expenses for 2022 totaled RMB 233,659,132, a decrease from RMB 248,153,842 in 2021, with RMB 226,850,903 recognized in profit or loss[178] Shareholder Equity and Dividends - The company distributed RMB 72,030,000 to shareholders in 2022, compared to RMB 52,150,000 in 2021, marking an increase of approximately 38.3%[34] - The total comprehensive income for 2022 was RMB 137,272,198, down from RMB 212,380,706 in 2021, reflecting a decrease of approximately 35.3%[34] - The company reported a total shareholder equity of RMB 2,321,921,130 as of December 31, 2022, reflecting a slight increase from the previous year[34] Inventory and Receivables - The company reported a decrease in inventory to RMB 40,526,760 in 2022 from RMB 35,625,222 in 2021, which is an increase of 13.4%[6] - The total accounts receivable balance as of December 31, 2022, is CNY 569,136,087, with an expected credit loss of CNY 14,777,342[138] - Accounts receivable as of December 31, 2022, total RMB 518,749,422, down from RMB 569,136,087 in 2021, indicating a decrease of approximately 8.8%[129] - The provision for bad debts for accounts receivable decreased to RMB 12,365,732 in 2022 from RMB 14,777,342 in 2021, reflecting a reduction of about 16.3%[133] Impairment and Provisions - The total impairment provision for assets decreased to CNY 16,229,937 from CNY 17,178,928 in 2021, reflecting a reduction of approximately 5.5%[190] - The provision for inventory write-down increased by CNY 3,052,947 during the year, resulting in a total of CNY 3,247,315 as of December 31, 2022, compared to CNY 4,771,622 in 2021[190] - The provision for bad debts for other receivables was zero as of December 31, 2022, compared to CNY (925) in 2021[151] Employee Compensation - The total employee compensation payable decreased to CNY 27,761,585 in 2022 from CNY 36,493,188 in 2021, reflecting a decline of about 24.5%[197] - The provision for employee benefits, including social insurance, was CNY 2,280,771 as of December 31, 2022, compared to CNY 491,727 in 2021, indicating a significant increase in employee-related expenses[199] Accounting Policies - The financial statements for the year 2022 were approved by the board of directors on March 27, 2023[41] - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete information[44] - The accounting year runs from January 1 to December 31, aligning with the calendar year[45] Other Financial Information - The company has adopted new accounting standards and interpretations issued by the Ministry of Finance, which had no significant impact on the financial statements[120] - The corporate income tax rate applicable to the company for the year 2022 is 15%, consistent with 2021[122] - The company has not recognized any taxable income for its subsidiary Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. for the years 2021 and 2022, resulting in no income tax expense[123]